LY3410738 + durvalumab

LY3410738 + durvalumab is an investigational combination therapy under clinical evaluation, primarily for cancers with isocitrate dehydrogenase 1 or 2 (IDH1/2) mutations, including advanced cholangiocarcinoma. LY3410738 is a potent, oral, covalent small molecule inhibitor that selectively targets both mutant IDH1 and IDH2 enzymes, binding irreversibly at a novel site to maintain efficacy even with secondary resistance mutations. Durvalumab is a human monoclonal antibody immune checkpoint inhibitor directed at programmed cell death ligand 1 (PD-L1), restoring and enhancing anti-tumor immune responses. The combination is currently evaluated in early phase clinical trials for safety, tolerability, and efficacy, with translational studies supporting its use in IDH-mutant cancers[1][3][5].